Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RallybioRLYB -1.33%28 EV-to-OCF is -0.13 as of Sep. 01, 2026. GuruFocus rates RLYB with a GF Score™ of 28/100. The stock has 5 warning signs investors should review. Among 1,408 Biotechnology companies, Rallybio ranks worse than 71.88% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Rallybio's Enterprise Value is $-3.53 Mil.
Rallybio's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $26.71 Mil. Therefore, Rallybio's EV-to-OCF for today is -0.13.
The historical rank and industry rank for Rallybio's EV-to-OCF or its related term are showing as below:
RLYB'
s EV-to-OCF Range Over the Past 10 Years
Min: -1.61 Med: 0.59 Max: 1.03
Current: -0.13
During the past 7 years, the highest EV-to-OCF of Rallybio was 1.03. The lowest was -1.61. And the median was 0.59.
RLYB's EV-to-OCF is ranked worse than 71.88% of 1408
companies
in the Biotechnology industry
Industry Median: -3.685
vs RLYB: -0.13
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Rallybio's share price for today is $16.82.
Rallybio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $7.920.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Rallybio EV-to-OCF Related Terms
Rallybio EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Rallybio's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Rallybio's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rallybio EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rallybio's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Rallybio's EV-to-OCF falls into.
Rallybio's current Enterprise Value is $-3.53 Mil.
Rallybio's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $26.71 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rallybio (RLYB) has a EV-to-OCF of -0.13 as of Sep. 01, 2026. According to the industry distribution chart, Rallybio ranks #1012 out of 1408 companies in the Biotechnology industry, placing it in the top 71.9%.
Is Rallybio's EV-to-OCF too high?
Rallybio's current EV-to-OCF is -0.13. Based on the distribution chart, Rallybio ranks #1012 out of 1408 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Rallybio has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Rallybio's EV-to-OCF compare to DWTX and ALDX?
According to the Biotechnology industry distribution chart, Rallybio ranks #1012 out of 1408 companies for EV-to-OCF. This places Rallybio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Rallybio's current EV-to-OCF is -0.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rallybio stock overvalued right now?
Rallybio (RLYB) has a current EV-to-OCF of -0.13. The current EV-to-OCF is -0.13. Rallybio's overall GF Score™ is 28/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Rallybio (RLYB), the current EV-to-OCF is -0.13 as of Sep. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.
28GF Score
Get the complete analysis for RLYB
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RLYB has been successfully added to your 
